Artivion
AORT NYSE· Health Care Equipment
Last close · Oct 27, 2026
$22.94
KIRA · Stoqly’s AI analyst, in plain words
- Artivion had $441M of revenue in fiscal 2025, up 13.6% on the year before. Over five years, revenue changed +11.8% a year on average.
- Its operating margin was 7.7%, down 2.4 pts: of every 100 in sales, about 8 is left after running the business.
- Artivion made $9.8M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −4.6% a year.
- Free cash flow was $0.8M in fiscal 2025, 0.2% of revenue.
- Artivion returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 13.2%.
- Artivion owes $154M more than it holds in cash, about 2.7 years of operating profit.
Market cap
$1.1B
P/E
—
Revenue
$441M
Net income
$9.8M
Free cash flow
$0.8M
Operating margin
7.7%
Artivion in 30 seconds · fiscal 2025
Are sales growing?
+13.6%
Yes. Sales grew 13.6% last year.
Does it make a profit?
2.2%
A little. It keeps 2.2% of every sale as profit.
Does profit turn into cash?
0.2%
Partly. 0.2% of sales ends up as free cash.
Is debt under control?
2.7x
Keep an eye on it. Repaying its debt would take 2.7 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
What Artivion does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 18, 2026
- Legal name
- ARTIVION, INC.
- CIK
- 0000784199
Artivion · AORT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $299M | $314M | $354M | $389M | $441M |
| Revenue growth | 18.0% | 5.0% | 12.8% | 9.8% | 13.6% |
| Gross margin | 66.1% | 64.5% | 64.7% | 64.0% | 64.4% |
| Operating margin | 2.7% | 2.0% | 1.6% | 10.0% | 7.7% |
| Net income | −$14.8M | −$19.2M | −$30.7M | −$13.4M | $9.8M |
| Net margin | −5.0% | −6.1% | −8.7% | −3.4% | 2.2% |
| Diluted EPS | −$0.38 | −$0.48 | −$0.75 | −$0.32 | $0.21 |
| Cash | |||||
| Cash from operations | −$2.6M | −$5.2M | $18.8M | $22.2M | $39.9M |
| Capital expenditure | $13.1M | $10.7M | $9.8M | $11.2M | $39.0M |
| Free cash flow | −$15.7M | −$15.9M | $9.1M | $11.1M | $0.8M |
| FCF margin | −5.3% | −5.1% | 2.6% | 2.8% | 0.2% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 3.0% | 2.7% | 1.8% | 2.3% | 13.2% |
| Debt and strength | |||||
| Cash and short-term investments | $55.0M | $39.4M | $58.9M | $53.5M | $64.9M |
| Debt incl. finance leases | $314M | $312M | $311M | $318M | $219M |
| Shareholders' equity | $301M | $284M | $282M | $276M | $448M |
| Net debt / EBITDA | 8.1x | 9.5x | 8.8x | 4.2x | 2.7x |
| Current ratio | 5.5x | 5.0x | 4.9x | 4.3x | 3.5x |
| Interest coverage | 0.5x | 0.3x | 0.2x | 1.1x | 1.3x |
| Returns and quality | |||||
| Return on capital | 1.1% | 0.9% | 0.8% | 5.7% | 3.9% |
| Return on equity | −4.7% | −6.6% | −10.8% | −4.8% | 2.7% |
| Piotroski F-score | 4 | 2 | 5 | 4 | 7 |
| Altman Z'' | 2.4 | 2.3 | 2.3 | 2.5 | 3.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$20.7M
8 insiders
Of sales under plans
24%
$4.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Artivion · AORT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Artivion AORT | $1.1B | 13.6% | 7.7% | 0.2% | 3.9% | — | 7 |
| Glaukos GKOS | $10.7B | 32.3% | −39.3% | −4.4% | — | — | — |
| LeMaitre Vascular LMAT | $2.1B | 13.5% | 27.2% | 29.8% | 25.5% | 29.4x | 5 |
| Inspire Medical Systems INSP | $2.1B | 13.6% | 5.6% | 8.6% | 14.2% | 15.7x | 5 |
| CONMED CNMD | $1.5B | 5.2% | 7.5% | 11.0% | 3.7% | — | 6 |
KIRA
At $22.94 a share, the company is worth $1.1B.
Artivion grew sales faster than 2 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0000784199). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.